全文获取类型
收费全文 | 35559篇 |
免费 | 2114篇 |
国内免费 | 160篇 |
专业分类
耳鼻咽喉 | 508篇 |
儿科学 | 827篇 |
妇产科学 | 634篇 |
基础医学 | 4216篇 |
口腔科学 | 657篇 |
临床医学 | 3445篇 |
内科学 | 8438篇 |
皮肤病学 | 414篇 |
神经病学 | 3351篇 |
特种医学 | 1432篇 |
外国民族医学 | 1篇 |
外科学 | 6219篇 |
综合类 | 224篇 |
一般理论 | 18篇 |
预防医学 | 2090篇 |
眼科学 | 473篇 |
药学 | 2024篇 |
中国医学 | 45篇 |
肿瘤学 | 2817篇 |
出版年
2024年 | 25篇 |
2023年 | 205篇 |
2022年 | 394篇 |
2021年 | 891篇 |
2020年 | 543篇 |
2019年 | 883篇 |
2018年 | 1090篇 |
2017年 | 749篇 |
2016年 | 767篇 |
2015年 | 923篇 |
2014年 | 1358篇 |
2013年 | 1832篇 |
2012年 | 2692篇 |
2011年 | 2893篇 |
2010年 | 1643篇 |
2009年 | 1579篇 |
2008年 | 2485篇 |
2007年 | 2623篇 |
2006年 | 2445篇 |
2005年 | 2364篇 |
2004年 | 2135篇 |
2003年 | 2001篇 |
2002年 | 1798篇 |
2001年 | 274篇 |
2000年 | 173篇 |
1999年 | 240篇 |
1998年 | 393篇 |
1997年 | 310篇 |
1996年 | 223篇 |
1995年 | 224篇 |
1994年 | 183篇 |
1993年 | 176篇 |
1992年 | 98篇 |
1991年 | 112篇 |
1990年 | 88篇 |
1989年 | 79篇 |
1988年 | 60篇 |
1987年 | 58篇 |
1986年 | 59篇 |
1985年 | 69篇 |
1984年 | 88篇 |
1983年 | 88篇 |
1982年 | 84篇 |
1981年 | 80篇 |
1980年 | 66篇 |
1979年 | 38篇 |
1978年 | 37篇 |
1977年 | 27篇 |
1975年 | 24篇 |
1974年 | 24篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
992.
Patient‐Reported Defecation and Micturition Problems Among Adults Treated for Sacrococcygeal Teratoma During Childhood—The Need for New Surveillance Strategies 下载免费PDF全文
993.
Quantitative assessment of the upper airway in infants and children with subglottic stenosis 下载免费PDF全文
994.
Marijke E. B. Kremer Joep P. M. Derikx Leontien C. M. Kremer Robertine van Baren Hugo A. Heij Marc H. W. A. Wijnen René M. H. Wijnen David C. van der Zee L. W. Ernest van Heurn 《Pediatric surgery international》2016,32(3):261-268
Purpose
The impact of chemotherapeutic sequelae on long-term quality of life (QoL) for survivors of malignant sacrococcygeal teratoma (SCT) is unknown. The incidence of chemotherapeutic toxicity in patients treated for malignant SCT and possible effects on the QoL were analyzed.Methods
Retrospective chart review of patients ≥18 years treated for SCT in the Netherlands was performed. Present QoL was evaluated using the SF-36 questionnaire. The results of survivors of malignant SCT were compared to those of patients treated for benign SCT.Results
Fifty-one of 76 traceable patients consented to participate. The results of 47 (92.2 %), 9 men and 38 women (median age 25.4 years, range 18.3–41.2), were analyzed. Eleven had been treated for malignancy; 63.6 % suffered from at least one chemotherapeutic sequel with hearing loss as the most common one. Results for both groups were similar on all but one SF-36 subcategory; those treated for malignant tumor scored significantly lower on the subcategory physical functioning (p = 0.02).Conclusion
Despite the high incidence of chemotherapeutic sequelae among survivors of malignant SCT, their QoL does not differ from that of those treated for benign SCT. Even though their physical functioning is restricted, daily activities and psychosocial functioning of survivors of malignant SCT are not restricted.995.
Phase II trial of docetaxel,bevacizumab, lenalidomide and prednisone in patients with metastatic castration‐resistant prostate cancer 下载免费PDF全文
Ravi A. Madan Fatima H. Karzai Yang‐Min Ning Bamidele A. Adesunloye Xuan Huang Nancy Harold Anna Couvillon Guinevere Chun Lisa Cordes Tristan Sissung Shaunna L. Beedie Nancy A. Dawson Marc R. Theoret David G. McLeod Inger Rosner Jane B. Trepel Min‐Jung Lee Yusuke Tomita Sunmin Lee Clara Chen Seth M. Steinberg Philip M. Arlen James L. Gulley William D. Figg William L. Dahut 《BJU international》2016,118(4):590-597
996.
997.
998.
999.
Christine?Njuguna Annoesjka?Swart Marc?Blockman Gary?Maartens Briony?Chisholm Annemie?Stewart Anri?Uys Karen?CohenEmail author 《AIDS research and therapy》2016,13(1):40
Background
Gynaecomastia is associated with exposure to antiretroviral therapy (ART), in particular efavirenz. There is limited data on clinical characteristics of patients with ART-associated gynaecomastia in resource-limited settings and little guidance on the optimal management of this adverse drug reaction (ADR). We describe the clinical characteristics, management and outcomes of gynaecomastia cases reported to the National HIV & Tuberculosis Health Care Worker Hotline in South Africa.Methods
We identified all gynaecomastia cases in adolescent boys and men on ART reported to the hotline between June 2013 and July 2014. We collected follow up data telephonically at monthly intervals to document clinical management and outcomes.Results
We received 51 reports of gynaecomastia between June 2013 and July 2014; 11% of the 475 patient-specific ADR queries to the hotline. All patients were on efavirenz-based ART. Mean age was 34 years (standard deviation 12) and seven were adolescents. The median onset of gynaecomastia was 15 months after efavirenz initiation (interquartile range 6–42). Gynaecomastia was bilateral in 29 patients (57%) and unilateral in 16 (31%). Serum testosterone was quantified in 25 of 35 patients with follow up data, and was low in 2 (8%). Efavirenz was replaced with an alternative antiretroviral in 29/35 patients (83%) and gynaecomastia improved in 20/29 (69%).Conclusions
Gynaecomastia was a frequently reported ADR in our setting, occurring with prolonged efavirenz exposure. Testosterone was low in the minority of tested cases. Most clinicians elected to switch patients off efavirenz, and gynaecomastia improved in the majority.1000.
Amit Chopra Alexandros Kalkanis Marc A. Judson 《Expert Review of Clinical Immunology》2016,12(11):1191-1208
Introduction: Numerous biomarkers have been evaluated for the diagnosis, assessment of disease activity, prognosis, and response to treatment in sarcoidosis. In this report, we discuss the clinical and research utility of several biomarkers used to evaluate sarcoidosis.
Areas covered: The sarcoidosis biomarkers discussed include serologic tests, imaging studies, identification of inflammatory cells and genetic analyses. Literature was obtained from medical databases including PubMed and Web of Science.
Expert commentary: Most of the biomarkers examined in sarcoidosis are not adequately specific or sensitive to be used in isolation to make clinical decisions. However, several sarcoidosis biomarkers have an important role in the clinical management of sarcoidosis when they are coupled with clinical data including the results of other biomarkers. 相似文献